CN112512516A - 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂 - Google Patents

用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂 Download PDF

Info

Publication number
CN112512516A
CN112512516A CN201980050102.5A CN201980050102A CN112512516A CN 112512516 A CN112512516 A CN 112512516A CN 201980050102 A CN201980050102 A CN 201980050102A CN 112512516 A CN112512516 A CN 112512516A
Authority
CN
China
Prior art keywords
amino
ethyl
chlorophenyl
benzyloxyphenylthio
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980050102.5A
Other languages
English (en)
Chinese (zh)
Inventor
C·科拉多
C·布赫尔
J·琼斯
P·盖尔盖伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prio Treatment Ltd
Original Assignee
Prio Treatment Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prio Treatment Ltd filed Critical Prio Treatment Ltd
Priority to CN202510467128.7A priority Critical patent/CN120284929A/zh
Publication of CN112512516A publication Critical patent/CN112512516A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980050102.5A 2018-07-27 2019-07-26 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂 Pending CN112512516A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510467128.7A CN120284929A (zh) 2018-07-27 2019-07-26 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2018-141411 2018-07-27
JP2018141411 2018-07-27
JP2019036598 2019-02-28
JP2019-036598 2019-02-28
PCT/JP2019/029524 WO2020022507A1 (ja) 2018-07-27 2019-07-26 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510467128.7A Division CN120284929A (zh) 2018-07-27 2019-07-26 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂

Publications (1)

Publication Number Publication Date
CN112512516A true CN112512516A (zh) 2021-03-16

Family

ID=69181631

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980050102.5A Pending CN112512516A (zh) 2018-07-27 2019-07-26 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂
CN202510467128.7A Pending CN120284929A (zh) 2018-07-27 2019-07-26 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510467128.7A Pending CN120284929A (zh) 2018-07-27 2019-07-26 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂

Country Status (11)

Country Link
US (1) US20210283073A1 (https=)
EP (1) EP3831370A4 (https=)
JP (1) JP7389486B2 (https=)
KR (1) KR102948053B1 (https=)
CN (2) CN112512516A (https=)
AU (1) AU2019311609B2 (https=)
BR (1) BR112021001376A2 (https=)
IL (1) IL280451B2 (https=)
MX (1) MX2021001039A (https=)
TW (1) TWI899057B (https=)
WO (1) WO2020022507A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021424131A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
EP4248958A3 (en) 2021-01-28 2024-01-03 Priothera SAS Methods of treatment with s1p receptor modulators
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101981030A (zh) * 2008-01-25 2011-02-23 艾尼纳制药公司 用于S1P1激动剂的二氢-1H-吡咯并[1，2-a]吲哚-1-基羧酸衍生物
CN105007981A (zh) * 2013-02-20 2015-10-28 诺华股份有限公司 在移植患者中治疗移植物抗宿主病
US20150361506A1 (en) * 2013-01-30 2015-12-17 Memorial Sloan-Kettering Cancer Center Donor kir3dl1 and hla-b subtypes and leukemia control in hla-compatible allogenic hematopoietic stem cell transplantation
WO2017153889A1 (en) * 2016-03-08 2017-09-14 Novartis Ag Treatment of hematopoietic stem cell transplant patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1431275B1 (en) 2001-09-27 2010-04-07 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
MXPA04002679A (es) 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
CN101014329B (zh) * 2004-07-16 2010-09-08 杏林制药株式会社 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物
EP1806338B1 (en) 2004-10-12 2016-01-20 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride and hydrates thereof. and intermediates the production thereof
SI1932522T1 (sl) 2005-10-07 2012-08-31 Kyorin Seiyaku Kk Terapevtsko sredstvo za jetrno bolezen, ki vsebuje 2-amino-1,3- propandiolni derivat kot aktivno sestavino
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
US10154989B2 (en) * 2015-09-17 2018-12-18 Emory University Methods of managing graft versus host disease (GvHD) using indole carboxyaldehydes or derivatives thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101981030A (zh) * 2008-01-25 2011-02-23 艾尼纳制药公司 用于S1P1激动剂的二氢-1H-吡咯并[1，2-a]吲哚-1-基羧酸衍生物
US20150361506A1 (en) * 2013-01-30 2015-12-17 Memorial Sloan-Kettering Cancer Center Donor kir3dl1 and hla-b subtypes and leukemia control in hla-compatible allogenic hematopoietic stem cell transplantation
CN105007981A (zh) * 2013-02-20 2015-10-28 诺华股份有限公司 在移植患者中治疗移植物抗宿主病
WO2017153889A1 (en) * 2016-03-08 2017-09-14 Novartis Ag Treatment of hematopoietic stem cell transplant patients

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RAYA MAWAD, ET AL *
RAYA MAWAD, ET AL: "移植物抗宿主病和移植物抗白血病效应的发生机制及分离策略的研究进展", 《中国病理生理杂志》, vol. 27, no. 12, pages 2423 - 140 *
陈赟: "异基因造血干细胞移植中GVL和GVHD的研究进展", 《实用检验医师杂志》, vol. 2, no. 2, pages 115 - 117 *

Also Published As

Publication number Publication date
MX2021001039A (es) 2021-04-12
KR102948053B1 (ko) 2026-04-06
WO2020022507A1 (ja) 2020-01-30
EP3831370A4 (en) 2022-04-27
IL280451B1 (en) 2025-06-01
BR112021001376A2 (pt) 2021-04-20
US20210283073A1 (en) 2021-09-16
TWI899057B (zh) 2025-10-01
JP7389486B2 (ja) 2023-11-30
KR20210040954A (ko) 2021-04-14
IL280451B2 (en) 2025-10-01
CA3106608A1 (en) 2020-01-30
TW202011948A (zh) 2020-04-01
AU2019311609A1 (en) 2021-02-04
CN120284929A (zh) 2025-07-11
AU2019311609B2 (en) 2024-09-26
EP3831370A1 (en) 2021-06-09
IL280451A (en) 2021-03-25
JPWO2020022507A1 (ja) 2021-08-05

Similar Documents

Publication Publication Date Title
EP2435041B1 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
HUP0302130A2 (hu) Kombinációs gyógyszerkészítmény és eljárás az előállításukra
CN112512516A (zh) 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂
WO2021037933A1 (en) Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
CN101568338B (zh) 化合物用于制备治疗白血病药物的用途
CA3106608C (en) Preparation for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
US20210315898A1 (en) Combination therapy for treating cancer
AU2017231000B2 (en) Treatment of hematopoietic stem cell transplant patients
EA048825B1 (ru) Препарат для подавления рецидива гематологической злокачественной опухоли у пациентов, перенесших трансплантацию гемопоэтических стволовых клеток
HK40050286A (en) Agent for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
HK40040825A (zh) 用於治疗癌症的组合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination